15 research outputs found
Assessments of Opportunities to Improve Antibiotic Prescribing in an Emergency Department: A Period Prevalence Survey
Full text link
Clinical impact of human metapneumovirus infections before and during the COVID-19 pandemic
No full textClinical impact of cerebrospinal fluid Gram stain and culture testing: A retrospective cohort study
No full textFactors associated with single-room assignment among patients admitted through the emergency department during influenza epidemics
No full textNovel dual multiplex real-time RT-PCR assays for the rapid detection of SARS-CoV-2, influenza A/B, and respiratory syncytial virus using the BD MAX open system
No full textBioFire® FilmArray® Pneumonia Panel for Severe Lower Respiratory Tract Infections: Subgroup Analysis of a Randomized Clinical Trial
No full textMultiplex PCR point of care testing versus routine, laboratory-based testing in the treatment of adults with respiratory tract infections: a quasi-randomised study assessing impact on length of stay and antimicrobial use
No full textHigh level efficacy in humans of a next-generation plasmodium falciparum anti-sporozoite vaccine: R21 in Matrix-M (TM) adjuvant
No full textIt remains a global health priority to develop a durable and highly efficacious malaria vaccine. The most advanced malaria vaccine candidate, RTS,S/AS01 has completed Phase III testing in a multicentre study across several African sites and demonstrates low-level (~30%) efficacy against clinical malaria in children aged 5-17 months after a three dose schedule. Efficacy wanes rapidly over time and there remain some safety concerns that require further assessment in the planned pilot deployment trials due to commence in Africa in 2018
High level efficacy in humans of a next-generation plasmodium falciparum anti-sporozoite vaccine: R21 in Matrix-M (TM) adjuvant
No full textIt remains a global health priority to develop a durable and highly efficacious malaria vaccine. The most advanced malaria vaccine candidate, RTS,S/AS01 has completed Phase III testing in a multicentre study across several African sites and demonstrates low-level (~30%) efficacy against clinical malaria in children aged 5-17 months after a three dose schedule. Efficacy wanes rapidly over time and there remain some safety concerns that require further assessment in the planned pilot deployment trials due to commence in Africa in 2018
